🔎 Trials Near Me

Home › Paraganglioma › Washington

Paraganglioma clinical trials in Washington, DC

6 studies for Paraganglioma are looking for participants at sites in and around Washington (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors

RecruitingPhase 1
  • National Institutes of Health Clinical Center, Bethesda · 7 mi away
Ages 18 to 120 · All sexes · Updated Oct 5, 2026 · NCT06041516

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

RecruitingPhase 1
  • National Institutes of Health Clinical Center, Bethesda · 7 mi away
Ages 18 to 120 · All sexes · Updated Oct 2, 2026 · NCT06479811

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

RecruitingPhase 2
  • National Institutes of Health Clinical Center, Bethesda · 7 mi away
Ages 18 to 100 · All sexes · Updated Aug 25, 2026 · NCT03206060

Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

RecruitingPhase 1/2
  • National Institutes of Health Clinical Center, Bethesda · 7 mi away
Ages 18 to 120 · All sexes · Updated Aug 18, 2026 · NCT06427798

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

RecruitingPhase 2
  • National Institutes of Health Clinical Center, Bethesda · 7 mi away
Ages 18 to 120 · All sexes · Updated May 19, 2026 · NCT06503146

Paraganglioma trials in other cities

Other studies in Washington

From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.